279 related articles for article (PubMed ID: 20490325)
41. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
Bjerre C; Knoop A; Bjerre K; Larsen MS; Henriksen KL; Lyng MB; Ditzel HJ; Rasmussen BB; Brünner N; Ejlertsen B; Laenkholm AV
Acta Oncol; 2013 Jan; 52(1):82-90. PubMed ID: 23205744
[TBL] [Abstract][Full Text] [Related]
42. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma.
Lin CS; Chang SC; Ou LH; Chen CM; Hsieh SS; Chung YP; King KL; Lin SL; Wei YH
Oncol Rep; 2015 Jun; 33(6):2924-34. PubMed ID: 25845386
[TBL] [Abstract][Full Text] [Related]
43. Prognostic role of progesterone receptor expression in a population-based analysis.
Caldarella A; Barchielli A
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
[TBL] [Abstract][Full Text] [Related]
44. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
45. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
Stevanovic L; Choschzick M; Moskovszky L; Varga Z
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
[TBL] [Abstract][Full Text] [Related]
46. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.
Annaratone L; Simonetti M; Wernersson E; Marchiò C; Garnerone S; Scalzo MS; Bienko M; Chiarle R; Sapino A; Crosetto N
Oncotarget; 2017 Mar; 8(12):18680-18698. PubMed ID: 28423635
[TBL] [Abstract][Full Text] [Related]
47. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
Shi YJ; Tsang JY; Ni YB; Tse GM
Oncologist; 2017 Apr; 22(4):487-490. PubMed ID: 28341760
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
[TBL] [Abstract][Full Text] [Related]
49. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
[TBL] [Abstract][Full Text] [Related]
50. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
51. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
52. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
53. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M
Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352
[TBL] [Abstract][Full Text] [Related]
54. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia.
Lin CH; Liau JY; Lu YS; Huang CS; Lee WC; Kuo KT; Shen YC; Kuo SH; Lan C; Liu JM; Kuo WH; Chang KJ; Cheng AL
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1807-14. PubMed ID: 19505913
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of Ki67 in Chinese women diagnosed with ER
Hu Y; Gu R; Zhao J; Yang Y; Liu F; Jin L; Chen K; Jia H; Wang H; Liu Q; Su F; Jia W
BMC Cancer; 2017 Jan; 17(1):28. PubMed ID: 28061893
[TBL] [Abstract][Full Text] [Related]
56. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
[TBL] [Abstract][Full Text] [Related]
57. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
58. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
Gevensleben H; Göhring UJ; Büttner R; Heukamp LC; Kunz G; Dimpfl T; Jackisch C; Ortmann O; Albert US; Bender R; De Snoo F; Krijgsman O; Glas AM; Ergönenc YH; Vogel C; Dykgers A; Langwieder C; Rees M; Anzeneder T
Int J Mol Med; 2010 Dec; 26(6):837-43. PubMed ID: 21042777
[TBL] [Abstract][Full Text] [Related]
59. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
60. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
